ATOS vs. ZVRA, ATXS, UPB, ANAB, GLUE, RGNX, AURA, TSHA, RVNC, and TERN
Should you be buying Atossa Therapeutics stock or one of its competitors? The main competitors of Atossa Therapeutics include Zevra Therapeutics (ZVRA), Astria Therapeutics (ATXS), Upstream Bio (UPB), AnaptysBio (ANAB), Monte Rosa Therapeutics (GLUE), REGENXBIO (RGNX), Aura Biosciences (AURA), Taysha Gene Therapies (TSHA), Revance Therapeutics (RVNC), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry.
Atossa Therapeutics vs.
Atossa Therapeutics (NASDAQ:ATOS) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.
Atossa Therapeutics has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500.
12.7% of Atossa Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 7.6% of Atossa Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Atossa Therapeutics has higher earnings, but lower revenue than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Atossa Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Zevra Therapeutics had 19 more articles in the media than Atossa Therapeutics. MarketBeat recorded 22 mentions for Zevra Therapeutics and 3 mentions for Atossa Therapeutics. Zevra Therapeutics' average media sentiment score of 0.60 beat Atossa Therapeutics' score of 0.51 indicating that Zevra Therapeutics is being referred to more favorably in the news media.
Atossa Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 743.17%. Zevra Therapeutics has a consensus price target of $21.57, suggesting a potential upside of 167.30%. Given Atossa Therapeutics' higher probable upside, equities analysts clearly believe Atossa Therapeutics is more favorable than Zevra Therapeutics.
Atossa Therapeutics has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -342.63%. Atossa Therapeutics' return on equity of -35.74% beat Zevra Therapeutics' return on equity.
Atossa Therapeutics received 209 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 65.22% of users gave Atossa Therapeutics an outperform vote.
Summary
Atossa Therapeutics and Zevra Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Atossa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Atossa Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ATOS) was last updated on 2/17/2025 by MarketBeat.com Staff